1. Antivirals against SARS-CoV-2 by autumn?
2. Department of Health and Social Care. UK government
secures groundbreaking covid-19 antivirals. 2021.
https://www.gov.uk/government/news/uk-government-secures-groundbreaking-covid-19-antivirals
3. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
4. Merck. Merck and Ridgeback’s investigational oral
antiviral molnupiravir reduced the risk of hospitalization or death by
approximately 50 percent compared to placebo for patients with mild or
moderate covid-19 in positive interim analysis of phase 3 study. Press
release, 1 Oct 2021.
https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
5. ClinicalTrials.gov. Efficacy and safety of
molnupiravir (MK-4482) in non-hospitalized adult participants with
covid-19 (MK-4482-002). 2020.
https://clinicaltrials.gov/ct2/show/NCT04575597